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ABSTRACT: Introduction: Hereditary inclusion body myopathy (hIBM) refers to a group of clinically and genetically heterogeneous diseases. The overlapping histochemical features of hIBM with other genetic disorders lead to low diagnostic rates with targeted single-gene sequencing. This is true for the most prevalent form of hIBM, GNEpathy. Therefore, we used wholeexome sequencing (WES) to determine whether a cohort of clinically suspected GNEpathy patients undiagnosed by targeted GNE analysis could be genetically characterized. Methods: Twenty patients with hIBM but undiagnosed by targeted GNE sequencing were analyzed by WES before data filtering on 306 genes associated with neuromuscular disorders. Results: Seven patients out of 20 were found to have diseasecausing mutations in genes associated with hIBM or genes allowing for hIBM in the differential diagnosis or associated with unexpected diagnosis. Discussion: Next-generation sequencing is an efficient strategy in the context of hIBM, resulting in a molecular diagnosis for 35% of the patients initially undiagnosed by targeted GNE analysis.
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Hereditary inclusion body myopathies (hIBM) represent a heterogeneous group of muscular disorders defined by the relatively nonspecific criterion of rimmed vacuoles on muscle biopsy. 1 GNEpathy, 2 caused by mutations in GNE (UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase; MIM*603824), 3 is the most common form of hIBM, with many clinical features overlapping with other forms of hIBM, implicating other genes or forms with yet unknown underlying genetic defects. Targeted analysis of GNE in a large, recently described French cohort with suspected GNEpathy provides only a 20% diagnostic yield (32 of 164 patients). 4 The present study evaluates the extent to which a cohort of clinically suspected GNEpathy patients undiagnosed by GNE-targeted analysis may be genetically characterized by implicating other genes previously known to cause neuromuscular disorders with whole-exome sequencing (WES) associated with data filtering for 306 genes of interest.
MATERIALS AND METHODS
We selected 20 unrelated index cases (ICs) with clinically suspected GNEpathy associated with rimmed vacuoles on muscle biopsy samples but for which no GNE disease-causing mutation had been identified by direct-targeted sequencing. Samples had been prepared and stored by the Center of Biological Resources, Department of Medical Genetics, La Timone Hospital, Marseille, and were used in accordance with the ethical recommendations of our institution and the Declaration of Helsinki. All patients gave their written consent prior to the genetic study, in accordance with French law.
WES was performed with the SureSelect Human All Exon Kit version 5 (Agilent Technologies, Santa Clara, CA) and the HiSeq 2000 (Illumina, San Diego, CA).
Sequencing data were processed on the Illumina pipeline (CASAVA1.8.2) before using GATK 5 variant calling and ANNOVAR 6 annotation with the GRCh37/hg19 human genome version; coverage statistics were computed in the Variant Analysis and Filtration Tool (VarAFT; http://varaft.eu, 2016), which uses BedTools. 7 VarAFT was also used to sort and filter the obtained variants.
Our initial analysis strategy focused on 306 genes that had previously been reported to cause neuromuscular disorders, selected from the Gene Table of Neuromuscular Disorders 8 (including groups 1 to 5 and the main differential diagnosis genes), as previously described.
9,10 A mean overall sequencing depth of 106X and a mean coverage of the coding exons of 95% (at 20X depth) and 91% (at 30X depth) was obtained for these 306 genes. Predicted pathogenicity of identified variants was determined with Universal Mutation Database (UMD)-predictor, 11 Sorting Intolerant From Tolerant (SIFT) human protein, 12 Polymorphism Phenotyping v2 (PolyPhen-2), 13 and Human Splicing Finder (HSF) 14 software. With regard to HSF 14 in silico results, we defined 4 types of predicted splicing effects: (1) probably damaging, associated with predicted strong splicing effect because of broken donor site (DS) or acceptor site (AS) and/or new DS/AS creation and/or strong possibility of broken exonic splicing enhancer (ESE) site; (2) possibly damaging, associated with predicted medium splicing effect relating to newly created DS/AS and/or medium possibility of broken ESE site; (3) uncertain, associated with predicted mild splicing effect because of newly created DS/AS and/or low possibility of broken ESE site; and (4) not affected, predicted weak or no splicing effect.
The overall pathogenicity score for each variant was determined according to the American College of Medical Genetics (ACMG) guidelines. 15 We established 4 groups of patients based on the degree of certainty of molecular diagnosis using the ACMG guidelines. The group with "definite diagnosis" consisted of (1) patients carrying a homozygous variant classified as "pathogenic" by ACMG guidelines in a gene known to cause an autosomal recessive form of disease; (2) compound heterozygotes carrying 2 variants classified as pathogenic; and (3) patients carrying 1 variant classified as pathogenic in a gene known to cause an autosomal dominant form of disease. The group with "probable diagnosis" was composed of patients carrying variants that were classified as "likely pathogenic" by ACMG guidelines. Patients carrying variants found to be pathogenic by certain prediction tools but classified as "variants of uncertain significance" by ACMG guidelines were placed in the group with "possible diagnosis." For those patients in the "no established diagnosis" group, no variant compatible with the patient's phenotype was found.
All disease-causing variants identified by WES were confirmed by direct-targeted sequencing with a genetic analyzer (3500XL; Thermo Fisher Scientific, Waltham, MA) and the following gene sequence references:
, and VCP (NM_007126).
RESULTS
All phenotypic and mutational data are detailed in Table 1 . A definite diagnosis was obtained for 7 ICs. Patient P1 harbored a previously reported mutation in TTN (titin; MIM*188840) associated with hereditary myopathy with early respiratory failure 16 ; the homozygous status of this mutation is consistent with the parental consanguinity. For patients P2 and P5, the same heterozygous mutation in VCP (valosin-containing protein; MIM *601023) previously described in the literature 17 was discovered and associated with similar onset and clinical features (distal myopathy of upper and lower limbs). Compound heterozygous known mutations in TTN 18, 19 were found in patient P3, whereas patient P4 harbored a previously described heterozygous variant in DES (desmin; MIM* 125660) 20 leading to cardiomyopathy and myofibrillar abnormalities on the muscle biopsy, features that were retrieved in patient P4. For patient P6, a known FLNC (filamin C; MIM *102565) mutation was found. 21 We were surprised to discover compound heterozygous mutations for the GYG1 (glycogenin 1; MIM*603942) gene in patient P7, associated with polyglucosan body myopathy type 2. In this patient, we found a previously described GYG1 variant with a proven deleterious effect on splicing, 22 associated with a novel GYG1 mutation leading to a frameshift of the reading frame and the introduction of a premature translation ACMG, American College of Medical Genetics; AD, autosomal dominant; AR, autosomal recessive; Comp. HTZ, compound heterozygous (with confirmed segregation analysis); F, female; HMREF, hereditary myopathy with early respiratory failure; DM, distal myopathy; HOZ, homozygous; HSF, human splicing finder; HTZ, heterozygous; M, male; NP, not performed (UMD-predictor, SIFT, and PolyPhen-2 algorithms do not provide a pathogenicity score for variants creating a stop or a frameshift); PM, proximal myopathy; PolyPhen-2, polymorphism phenotyping v2; SIFT, sort intolerant from tolerant; UMD-predictor, universal mutation database predictor; y, years of age. *Frequency in 1000G, ESP, and ExAC databases of all the variants described in Table 1 is lower than 0.2%. Boldface indicates that pathogenicity prediction is strong or moderate. † Additional variant with uncertain significance found for patient P9: MYH2: c.2090A>G (p.His697Arg). ‡ Variant affecting the same nucleic and amino acid positions as another variant, c.1127G>A (p.Gly376Asp), previously described in the literature [27] [28] [29] in two different familial amyotrophic lateral sclerosis cases with a similar phenotype presentation as patient P9 (upper and lower limb weakness with no cognitive impairment).
termination codon. Additional investigations showed additional clinical and histoimmunological features, suggesting a polyglucosan body myopathy (data not shown). A probable diagnosis was obtained for patients P8 and P9, with novel compound heterozygous TTN mutations and heterozygous TARDBP (tar DNA-binding protein; MIM *605078) variants, respectively, while two novel heterozygous variants in the FLNC and the ACTA1 (actin, alpha, skeletal muscle 1; MIM *102610) genes fulfilled the possible diagnosis overall pathogenicity score in patients P10 and P11, respectively. Nine ICs remained without a molecular diagnosis following mutational analysis of the 306 genes of interest. Considering only the first (definite) group of patients, the yield of diagnosed patients was 35% in this cohort (7/20) .
DISCUSSION
Next-generation sequencing (NGS) is already used by many genetics laboratories and is being used with increasing frequency as the standard initial analysis for myopathies and other heterogeneous genetic disorders. The molecular diagnosis yield of 35% obtained in this study is consistent with other reports showing a range of 25%-50% for rare genetic disorders diagnosis by WES. 23, 24 Our study illustrates that an NGS approach is more efficient than the gene-by-gene strategy for several reasons. First, it allowed us to explore genes responsible for disorders within the differential diagnosis of hIBM, including VCP and DES. Second, our strategy permitted sequencing of large-sized genes, such as TTN and FLNC, which is not routinely performed, leading to the identification of variants in 5 ICs. Third, this approach allowed us to modify the incorrect diagnosis of hIBM in 1 patient that had initially been based on the presence of rimmed vacuoles on muscle biopsy to a different muscle disorder caused by variants in the gene GYG1. Thus, NGS has the potential to alter a misdiagnosis resulting from a misleading muscle biopsy. Although using WES to explore a subset of genes might not provide as much target sequence coverage as a sequencing strategy specifically designed for these genes, 10 there are several advantages of using this approach. The sequencing results for samples where no pathogenic variants were identified in the initially explored genes can be reanalyzed to explore additional genes or all genes in the whole exome. In this way, further analyses are ongoing for the cases among our cohort that remain without genetic characterization. Another advantage of WES compared with targeted exome sequencing is its versatility and ability to be applied to many different diseases because different sets of genes can be assessed without the need for developing and testing a specific sequencing strategy. 25, 26 In conclusion, the exome-based sequencing strategy described here is an efficient way to diagnose genetically heterogeneous disorders such as hIBMs.
